Published in Lancet on May 14, 1988
Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest (1990) 2.16
Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ (1989) 1.60
Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ (1990) 1.50
Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease. BMJ (1993) 1.38
Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet (1991) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest (1994) 1.14
Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ (1989) 1.13
Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest (1992) 1.13
The age dependency of gene expression for plasma lipids, lipoproteins, and apolipoproteins. Am J Hum Genet (1997) 1.11
Lipoprotein(a) and its role in occlusive vascular disease. Ann R Coll Surg Engl (1993) 0.99
The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering. J Biol Chem (2011) 0.95
Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet (1992) 0.92
Lipoprotein (A): Better assessor of coronary heart disease risk in south Indian population. Indian J Clin Biochem (2004) 0.91
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
Circulating lipids and glycaemic control in insulin dependent diabetic children. Arch Dis Child (1994) 0.82
Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. World J Cardiol (2016) 0.80
Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery. Heart (1997) 0.79
Lipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease. Indian J Clin Biochem (2015) 0.79
Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease. Br Heart J (1993) 0.78
The binding of animal low-density lipoproteins to human apolipoprotein(a). Biochem J (1995) 0.77
The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction. Biochem J (1995) 0.77
Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease. J Clin Pathol (1995) 0.76
Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease. Cureus (2016) 0.75
Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. J Clin Pathol (1993) 0.75
Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J (1994) 0.75
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet (1999) 2.75
Cloning of the afl-2 gene involved in aflatoxin biosynthesis from Aspergillus flavus. Appl Environ Microbiol (1993) 2.71
Cloning of the Aspergillus parasiticus apa-2 gene associated with the regulation of aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.57
Molecular characterization of aflR, a regulatory locus for aflatoxin biosynthesis. Appl Environ Microbiol (1994) 2.56
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Comparative mapping of aflatoxin pathway gene clusters in Aspergillus parasiticus and Aspergillus flavus. Appl Environ Microbiol (1995) 2.33
Identification of O-methylsterigmatocystin as an aflatoxin B1 and G1 precursor in Aspergillus parasiticus. Appl Environ Microbiol (1987) 2.24
Cloning and characterization of a cDNA from Aspergillus parasiticus encoding an O-methyltransferase involved in aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.10
Effect of cholecystectomy on bowel function: a prospective, controlled study. Gut (1999) 2.08
Appearance of enzyme activities catalyzing conversion of sterigmatocystin to aflatoxin B1 in late-growth-phase Aspergillus parasiticus cultures. Appl Environ Microbiol (1987) 1.79
The thermodynamics of protein denaturation. 3. The denaturation of ribonuclease in water and in aqueous urea and aqueous ethanol mixtures. J Am Chem Soc (1967) 1.77
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Clinical predictors and radiological reliability in atlantoaxial subluxation in Down's syndrome. Arch Dis Child (1991) 1.68
Increased expression of Aspergillus parasiticus aflR, encoding a sequence-specific DNA-binding protein, relieves nitrate inhibition of aflatoxin biosynthesis. Appl Environ Microbiol (1995) 1.66
Insulin dependent diabetes in children under 5: incidence and ascertainment validation for 1992. BMJ (1995) 1.63
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Purification of a 40-kilodalton methyltransferase active in the aflatoxin biosynthetic pathway. Appl Environ Microbiol (1993) 1.52
Trichobezoar obstructing the terminal ileum. Trop Doct (2002) 1.51
Averufanin is an aflatoxin B1 precursor between averantin and averufin in the biosynthetic pathway. Appl Environ Microbiol (1987) 1.49
The Aspergillus parasiticus polyketide synthase gene pksA, a homolog of Aspergillus nidulans wA, is required for aflatoxin B1 biosynthesis. Mol Gen Genet (1995) 1.46
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Prediction of birthweight by fetal ultrasound biometry. Br J Radiol (1992) 1.41
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
Alberta. Suspected ivermectin toxicity in kittens. Can Vet J (1991) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Sequence variability in homologs of the aflatoxin pathway gene aflR distinguishes species in Aspergillus section Flavi. Appl Environ Microbiol (1995) 1.32
Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30). Proc Natl Acad Sci U S A (2004) 1.30
Structure and function of fas-1A, a gene encoding a putative fatty acid synthetase directly involved in aflatoxin biosynthesis in Aspergillus parasiticus. Appl Environ Microbiol (1996) 1.28
Lipid peroxidative damage on pyrethroid exposure and alterations in antioxidant status in rat erythrocytes: a possible involvement of reactive oxygen species. Toxicol Lett (1999) 1.27
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Attention and driving performance in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci (1998) 1.27
Characterization of the Aspergillus parasiticus niaD and niiA gene cluster. Curr Genet (1996) 1.24
Outcome in patients on continuous ambulatory peritoneal dialysis and haemodialysis: 4-year analysis of a prospective multicentre study. Lancet (1987) 1.23
Evidence for de novo synthesis of an aflatoxin pathway methyltransferase near the cessation of active growth and the onset of aflatoxin biosynthesis in Aspergillus parasiticus mycelia. Can J Microbiol (1990) 1.20
Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res (1998) 1.19
Molecular characterization of an Aspergillus parasiticus dehydrogenase gene, norA, located on the aflatoxin biosynthesis gene cluster. Appl Environ Microbiol (1996) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Parent-infant cosleeping: the appropriate context for the study of infant sleep and implications for sudden infant death syndrome (SIDS) research. J Behav Med (1993) 1.15
Lifestyle behaviours of young adult survivors of childhood cancer. Br J Cancer (2002) 1.15
Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis (1991) 1.14
Life events and low birthweight--analysis by infants preterm and small for gestational age. Br J Obstet Gynaecol (1991) 1.13
stcS, a putative P-450 monooxygenase, is required for the conversion of versicolorin A to sterigmatocystin in Aspergillus nidulans. Appl Environ Microbiol (1995) 1.13
The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Clin Pharmacol Ther (2011) 1.13
Characterization of aflJ, a gene required for conversion of pathway intermediates to aflatoxin. Appl Environ Microbiol (1998) 1.12
Adenosine cyclic 3',5'-monophosphate dependent protein kinase: a new fluorescence displacement titration technique for characterizing the nucleotide binding site on the catalytic subunit. Biochemistry (1983) 1.11
Characterization of the critical amino acids of an Aspergillus parasiticus cytochrome P-450 monooxygenase encoded by ordA that is involved in the biosynthesis of aflatoxins B1, G1, B2, and G2. Appl Environ Microbiol (1998) 1.11
Protective effect of vitamin E in dimethoate and malathion induced oxidative stress in rat erythrocytes. J Nutr Biochem (2001) 1.09
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
Variability among atoxigenic Aspergillus flavus strains in ability to prevent aflatoxin contamination and production of aflatoxin biosynthetic pathway enzymes. Appl Environ Microbiol (1994) 1.05
avnA, a gene encoding a cytochrome P-450 monooxygenase, is involved in the conversion of averantin to averufin in aflatoxin biosynthesis in Aspergillus parasiticus. Appl Environ Microbiol (1997) 1.04
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Cadmium-induced lipid peroxidation and the status of the antioxidant system in rat tissues. J Trace Elem Med Biol (1995) 1.03
The effect of elevated temperature on gene transcription and aflatoxin biosynthesis. Mycologia (2007) 1.03
C(15)H(24) Volatile Compounds Unique to Aflatoxigenic Strains of Aspergillus flavus. Appl Environ Microbiol (1993) 1.03
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Individual reaction requirements of two enzyme activities, isolated from Aspergillus parasiticus, which together catalyze conversion of sterigmatocystin to aflatoxin B1. Can J Microbiol (1987) 1.00
POSSUM and P-POSSUM for risk-adjusted audit of patients undergoing emergency laparotomy. Br J Surg (2004) 0.99
Action of capparis decidua against alloxan-induced oxidative stress and diabetes in rat tissues. Pharmacol Res (1997) 0.99
Cloning and characterization of avfA and omtB genes involved in aflatoxin biosynthesis in three Aspergillus species. Gene (2000) 0.99
Elucidation of veA-dependent genes associated with aflatoxin and sclerotial production in Aspergillus flavus by functional genomics. Appl Microbiol Biotechnol (2007) 0.99
A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol (1987) 0.98
Experimental studies of infant-parent co-sleeping: mutual physiological and behavioral influences and their relevance to SIDS (sudden infant death syndrome). Early Hum Dev (1994) 0.98
Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol (1992) 0.97
Comparison of the omtA genes encoding O-methyltransferases involved in aflatoxin biosynthesis from Aspergillus parasiticus and A. flavus. Gene (1995) 0.97
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
Lipid peroxidative damage on cadmium exposure and alterations in antioxidant system in rat erythrocytes: a study with relation to time. Biometals (1998) 0.97
The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J (2004) 0.97
One gene to whole pathway: the role of norsolorinic acid in aflatoxin research. Adv Appl Microbiol (1997) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Genes encoding cytochrome P450 and monooxygenase enzymes define one end of the aflatoxin pathway gene cluster in Aspergillus parasiticus. Appl Microbiol Biotechnol (2000) 0.96
Hybridization of genes involved in aflatoxin biosynthesis to DNA of aflatoxigenic and non-aflatoxigenic aspergilli. Appl Microbiol Biotechnol (1995) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev (2009) 0.95
Amino acid supplementation reveals differential regulation of aflatoxin biosynthesis in Aspergillus flavus NRRL 3357 and Aspergillus parasiticus SRRC 143. Appl Microbiol Biotechnol (2007) 0.94
The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis (2000) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94
Conversion of a new metabolite to aflatoxin B2 by Aspergillus parasiticus. Appl Environ Microbiol (1987) 0.93
Dietary intake and the insulin-like growth factor system: effects of migration in two related populations in India and Britain with markedly different dietary intake. Public Health Nutr (2005) 0.93
Repressor-AFLR interaction modulates aflatoxin biosynthesis in Aspergillus parasiticus. Mycopathologia (1999) 0.93
Generation of aflR disruption mutants of Aspergillus parasiticus. Appl Microbiol Biotechnol (2000) 0.93
Proton release in photosynthetic water oxidation: evidence for proton movement in a restricted domain. Biochemistry (1981) 0.93
Cloning of a sugar utilization gene cluster in Aspergillus parasiticus. Biochim Biophys Acta (2000) 0.93
Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc Natl Acad Sci U S A (1990) 0.93
Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest (2000) 0.92
Molecular characterization of the afl-1 locus in Aspergillus flavus. Appl Environ Microbiol (1995) 0.92
Characterization of experimentally induced, nonaflatoxigenic variant strains of Aspergillus parasiticus. Appl Environ Microbiol (1996) 0.92